Mineralys Therapeutics
Trade Mineralys Therapeutics 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About MLYS
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease.
MLYS Key Statistics
Stock Snapshot
Mineralys Therapeutics(MLYS) stock is priced at $30.87, giving the company a market capitalization of 2.44B. It carries a P/E multiple of -10.44.
As of 2026-02-03, Mineralys Therapeutics(MLYS) stock has fluctuated between $30.37 and $31.40. The current price stands at $30.87, placing the stock +1.6% above today's low and -1.7% off the high.
The Mineralys Therapeutics(MLYS)'s current trading volume is 774.44K, compared to an average daily volume of 897.18K.
During the past year, Mineralys Therapeutics(MLYS) stock moved between $8.24 at its lowest and $47.65 at its peak.
During the past year, Mineralys Therapeutics(MLYS) stock moved between $8.24 at its lowest and $47.65 at its peak.
Analyst ratings
88%
of 8 ratingsPeople also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.